1. [Is short-course therapy enough at drug-resistant tuberculosis?]
- Author
-
Tülay Törün, Elif Yildirim, Ipek Ozmen, Haluk C. Çalişir, Hamza Ogun, and OGUN, HAMZA
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Tuberculosis ,Adolescent ,Treatment outcome ,Antitubercular Agents ,OGUN H., Ozmen I., Ozari Yildirim E., Torun T., Calisir H. C. , -Is short-course therapy enough at drug-resistant tuberculosis?-, TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.66, ss.280-287, 2018 ,Drug resistance ,Critical Care and Intensive Care Medicine ,Young Adult ,Internal medicine ,Tuberculosis, Multidrug-Resistant ,Medicine ,Humans ,Short course ,Young adult ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Standard treatment ,fungi ,food and beverages ,Retrospective cohort study ,Mycobacterium tuberculosis ,Middle Aged ,medicine.disease ,Multiple drug resistance ,Treatment Outcome ,Surgery ,Female ,business - Abstract
Introduction Tuberculosis drug resistance can be assessed by physicians with different approaches on issues such as the choice of treatment protocol and duration of treatment. Materials and methods In this study, we aimed to evaluate the treatment regimens and treatment results of patients with non multi-drug resistant tuberculosis (MDR-TB) drug resistance implemented in different chest disease clinics in our hospital. The 167 culture-positive patients with nonMDR-TB drug resistance diagnosed between 2008-2010 were analyzed retrospectively. Patients' age, gender, previous TB treatments, bacteriological cruise, drug resistance patterns and treatment outcomes were analyzed. Result One hundred sixty-seven patients with eligible data were evaluated; there were 117 (70.1%) men and 50 (29.9%) women, mean age was 42.35 (18-90) years, respectively. Among mono drug resistance; H resistance in 75 (44.9%) patients and R resistance in 11 patients was detected. In 19 (11.4%) patients HS resistance was detected as multiple drug resistance. One hudred and twenty-five (74.9%) were new cases. When treatment the results of in all patients evaluated, 136 (81.4%) of the patients achieved treatment success. Sixty-four (51.2%) of the new TB cases treated with "standard treatment protocols for new cases" (2HRZE/4H) and 51 (40.8%) of them treated with "other treatment protocols". Ten (23.8%)of the recurrent TB cases" standard treatment for recurrent cases (2HRZES/HRZE/5HRE) and 9 (21.4%) 33 (19.8%) of them treated with other protocols. The combination of the rthe treatment protocol and descriptive information about the duration of the treatment could not be created as 33 (19.8%) of the cases left without completing their treatment. Conclusions As a result of the analysis, patients have completed their treatment, there was no significant difference in treatment outcomes. Patients with Non MDR-TB drug resistance should be monitored well and should be careful in terms of MDR-TB.
- Published
- 2019